anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Alcohol use is a significant risk factor of disability and death for U.S. adults and one out of every six Veterans seen in primary care report unhealthy alcohol use. Based on substantial evidence from randomized controlled trials and the U.S. Preventive Services Task Force, VA/DoD clinical guidelines stipulate that all Veterans screening positive for unhealthy alcohol use should receive evidence-based alcohol care in primary care, including brief counseling interventions (BI) and additional treatment (e.g., pharmacotherapy) for those with alcohol use disorders (AUD). The VA was a pioneer in implementing alcohol screening and BI in primary care, yet substantial implementation gaps remain. In order to improve the quality and fidelity of alcohol-related care, the current research proposes to use an evidence-based implementation strategy, practice facilitation, at one VA to pilot test whether practice facilitation has the potential to improve quality of primary care-based alcohol-related care.

The project will first conduct qualitative interviews assessing Veteran and clinical stakeholders to understand barriers and facilitators to high-quality alcohol care. Results from qualitative interviews will be used to refine and hone the practice facilitation intervention. Clinical stakeholders will then be recruited to participate in focus groups in order to evaluate the acceptability and feasibility of the proposed practice facilitation intervention prior to testing it. Last, a pilot test of the practice facilitation intervention will be conducted within one VA primary care clinic to understand whether practice facilitation improves the quality of primary care-based alcohol-related care.
1. An infusion having high ameliorating effect and a medical action based on a plant raw material, characterized in that contains AVENA SATIVA L. of milky ripeness as the plant raw material. 2. A preparation having high ameliorating effect a and medical action based on the plant raw material water-alcohol extraction, characterized in that contains extractive agents, obtained by water-alcohol extraction of AVENA SATIVA L. of milky ripeness, and 20-70% ethyl alcohol with the following ratio of components, % by weight: extractive agents AVENA SATIVA L. of milky ripeness	0,1-15 20-70% ethyl alcohol	remaining 3. A preparation having high ameliorating effect a and medical action based on the plant raw material water-alcohol extraction, characterized in that contains extractive agents, obtained by water-alcohol extraction of AVENA SATIVA L. of milky ripeness, and water with the following ratio of components, % by weight: extractive agents AVENA SATIVA L. of milky ripeness	0,1-15 water	remaining 4. A process for obtaining a preparation having high amelioration effect and a medical action containing extraction of a plant raw material, characterized in that contains AVENA SATIVA L. of milky ripeness as the plant raw material, and extraction is carried out by 20-75% ethyl alcohol. 5. The process as claimed in claim 4, characterized in that newly-mowed or dried panicles of leafs and stems of AVENA SATIVA L. of milky ripeness up to 20 cm long. 6. The process as claimed in claim 5, characterized in that the extraction is carried out by percolation or maceration. 7. The process as claimed in claim 4 and 5, characterized in that the extraction is carried out during 1-168 hours. 8. The process as claimed in claim 7, characterized in that the extract is clarified at a temperature of 5-15 degree C during 24-120 hours in dark. 9. The process as claimed in claims 4 to 7, characterized in that the extract is thickened to a concentration of 5-30% of air-dried materials. 10. The process as claimed in claim 9, characterized in that the concentrate of extract is dried.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, and is intended for conservative therapy of chronic ductoforitis, accompanied by syndrome of pathologic secretion. Method includes antibacterial and antiproliferative therapy. Antibacterial therapy is carried out locally by means of ductal lavage taking into account sensitivity of microflora to antibiotics. Ductal lavage is carried out with application of 0.3% fluoroquinolone or 2.5% cephalosporin. Daily per 7 procedures for each affected milk duct. After that, antiproliferative therapy by medication "Epigallat" in dose 500 mg 2 capsules 2 times per day in the morning and in the evening after meal. Day dose is 2000 mg. Course duration is from 3 to 6 months depending on treatment result. ^ EFFECT: invention makes it possible to increase efficiency of conservative treatment and reduce frequency of surgical interventions. ^ 1 ex
Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%.
A method for continuously detecting body physiological information trajectories through the use of a personal wearable device. Through short-distance wireless transmission, a smartphone or a computer first transmits basic information, including a personal ID of a user of the device, a device ID, an ID of the smartphone or the computer, and communication links, to a remote medical data center. In this case, the device continuously detects body physiological information which can be transmitted to the remote medical data center. Corrective body physiological information data of the user is measured and transmitted to the remote medical data center. The remote medical data center processes the data and periodic pulse volume curves. The remote medical data center then transmits the numeral data converted from periodic pulse volume curves back to the personal wearable device and continuously constructs a periodic trajectory of detected personal body physiological information.
Chromosomal abnormalities are a common cause of human miscarriage but rarely reported in any other species. As a result, there are currently inadequate animal models available to study this condition. Horses present one potential model since mares receive intense gynecological care. This allowed us to investigate the prevalence of chromosomal copy number aberrations in 256 products of conception (POC) in a naturally occurring model of pregnancy loss (PL). Triploidy (three haploid sets of chromosomes) was the most common aberration, found in 42% of POCs following PL over the embryonic period. Over the same period, trisomies and monosomies were identified in 11.6% of POCs and subchromosomal aberrations in 4.2%. Whole and subchromosomal aberrations involved 17 autosomes, with chromosomes 3, 4, and 20 having the highest number of aberrations. Triploid fetuses had clear gross developmental anomalies of the brain. Collectively, data demonstrate that alterations in chromosome number contribute to PL similarly in women and mares, with triploidy the dominant ploidy type over the key period of organogenesis. These findings, along with highly conserved synteny between human and horse chromosomes, similar gestation lengths, and the shared single greatest risk for PL being advancing maternal age, provide strong evidence for the first animal model to truly recapitulate many key features of human miscarriage arising due to chromosomal aberrations, with shared benefits for humans and equids.
The invention provides a quilt with the functions of preventing shoulder aches and soothing the nerves. The quilt comprises a quilt core and a quilt cover. A containing groove for containing herbal medicine bags is formed in one end of the quilt core. A quilt core lining is arranged on the outer side of the quilt core. One end of the quilt core lining is fixed into the containing groove. A plurality of shoulder protecting parts are arranged on the quilt cover. Any one or combination of any two of sponge and compressed cotton is arranged in each shoulder protecting part. Fixing cloth straps are arranged at the ends of the shoulder protecting parts. A plurality of fixing holes are formed in the fixing cloth straps. A plurality of fixing buttons used in cooperation with the fixing holes are arranged on the quilt cover. The herbal medicine bags are prepared from, by weight, 11-20 parts of lilies, 20-25 parts of wild chrysanthemum flowers, 36-45 parts of lavender, 10-18 parts of tulip, 12-17 parts of folium artemisiae argyi, 15-20 parts of arabian jasmine flowers, 5-9 parts of radix saposhnikoviae, 8-10 parts of notopterygium roots, 5-8 parts of herba asari cum radice, 6-12 parts of flos magnolia, 13-20 parts of fructus gardenia, 7-13 parts of rhizoma atractylodis macrocephalae and 4-7 parts of the bark of eucommia. The quilt is simple in structure, reasonable in design, low in cost and capable of achieving the effects of soothing the nerves and resisting bacteria, meanwhile, the shoulders can be supported, and it is avoided that the shoulders catch a cold to cause aches.
The objective of this study is to assess the safety and performance of the Shockwave M5+ Peripheral IVL System to treat calcified peripheral arteries in pre-market countries, and to assess continued safety and effectiveness in the US. A minimum of 40 lesions in up to 40 subjects at up to 10 sites in Australia, New Zealand and the US will be enrolled with the aim of treating at least 20 target lesions with the 8.0 mm IVL catheter. A maximum of three target lesions may be treated per subject. Subjects with moderate and severely calcified iliac and femoropopliteal artery disease presenting with Rutherford Category 2 to 5. Approximately 6 months of enrollment at up to 10 sites in Australia, New Zealand and the US. Study subjects will be followed through discharge, 30 days, 6 and 12 months. Duplex Ultrasound (DUS) assessments will be completed at 12 months. Total anticipated study duration is 18 months. The primary safety endpoint is Major Adverse Events (MAE) at 30 days defined as: need for emergency surgical revascularization of target limb; unplanned target limb major amputation (above the ankle); symptomatic thrombus or distal emboli that require surgical, mechanical or pharmacologic means to improve flow and extend hospitalization ; or perforations that require an intervention, including bail-out stenting. The primary performance endpoint is technical success defined as final residual stenosis ≤30% without flow-limiting dissection (≥ Grade D) of the lesion by angiographic core lab.
FIELD: medicine. ^ SUBSTANCE: invention belongs to medicine, notably to dermatology and can be used for treatment of patients with acantholytic pemphigus. Treatment includes 10-15 intramuscular injections of Interal (interferon2 alpha), 1 million IU injection every second day. Ingestion of prednisolone at the rate of 1 mg/kg daily during 10 days is administered. Then dose is decreased by 2.5 mg every three days. ^ EFFECT: method allows diminish maximal daily dose of hormone approximately by factor 1,3, shorten drug intake duration, shorten length of hospital stay approximately by 50% and considerably reduce rate of complications. ^ 3 tbl, 2 ex
BACKGROUND: Identifying treatment targets for sarcopenia is a public health concern. This study aimed to examine the association of nocturnal sleep duration and midday napping with the presence of sarcopenia in middle-aged and older adults, utilizing data from the China Health and Retirement Longitudinal Study in 2011 and 2015.
METHODS: A sum of 7,926 individuals (≥40 years) took part in this study. Sarcopenia was diagnosed according to the Asian Working Group for Sarcopenia. A self-reported questionnaire was used to collect data on nocturnal sleep duration and midday napping. Nocturnal sleep duration was categorized into three groups: short sleepers (<6 h), normal sleepers (6-8 h), and long sleepers (>8 h). Midday napping was coded as a dichotomous outcome (yes/no).
RESULTS: The incidence of sarcopenia was 5.3% during the 4-year follow-up. Short sleep duration (<6 h) was substantially linked to an increased incidence of sarcopenia (OR: 1.50, 95% CI: 1.21-1.87) as compared to nocturnal sleep length (6-8 h). Adults with midday napping had a lower risk of developing sarcopenia than non-nappers (OR: 0.78, 95% CI: 0.63-0.95). We further found that short sleepers with midday napping did not have a significantly higher risk of subsequent diagnosis of sarcopenia compared to normal sleepers without midday napping.
CONCLUSION: These findings imply that short sleep duration in middle-aged and older persons is related to an increased incidence of sarcopenia. However, the adverse effect of short sleep duration on sarcopenia can be compensated by midday napping.
BACKGROUND: Although surveys and apps are available for women to report urination and bladder symptoms, they do not include their decisions regarding toileting. Real-world factors can interfere with toileting decisions, which may then influence bladder health. This premise lacks data per want of a robust data collection tool.
OBJECTIVE: The Prevention of Lower Urinary Tract Symptoms (PLUS) research consortium engaged a transdisciplinary team to build and test WhereIGo, a mobile data collection app for Android and iOS. The design goal was a comprehensive reporting system for capturing environmental, sociocultural, and physical factors that influence women's decisions for toileting. Aims include having (1) an innovative feature for reporting physiologic urge sensation when "thinking about my bladder" and shortly before "I just peed," (2) real-time reporting along with short look-back opportunities, and (3) ease of use anywhere.
METHODS: The development team included a plain language specialist, a usability specialist, creative designers, programming experts, and PLUS scientific content experts. Both real-time and ecological momentary assessments were used to comprehensively capture influences on toileting decisions including perceived access to toileting, degree of busyness or stress or focus, beverage intake amount, urge degree, or a leakage event. The restriction on the maximal number of taps for any screen was six. PLUS consortium investigators did pilot-testing. Formal usability testing relied on the recruitment of community-dwelling women at four PLUS research sites. Women used the app for 2 consecutive days. Outcome measures were the system usability scale (SUS; 0-100 range) and the functional Mobile Application Rating Scale (1-5 range). These scales were embedded at the end of the app. The estimated a priori sample size needed, considering the SUS cut point score set at ≥74, was 40 women completing the study.
RESULTS: Funding was provided by the National Institute of Diabetes and Digestive and Kidney Diseases since July 2015. The integrity of the build process was documented through multiple 5-minute videos presented to PLUS Consortium and through WhereIGo screenshots of the final product. Participants included 44 women, with 41 (93%) completing data collection. Participants ranged in age from 21 to 85 years, were predominantly non-Hispanic White (n=25, 57%), college-educated (n=25, 57%), and with incomes below US $75,000 (n=27, 62%). The SUS score was 78.0 (SE 1.7), which was higher than 75% of the 500 products tested by the SUS developers. The mean functional Mobile Application Rating Scale score was 4.4 (SE 0.08). The build and informal acceptability testing were completed in 2019, enrollment for formal usability testing completed by June 2020, and analysis was completed in 2022.
CONCLUSIONS: WhereIGo is a novel app with good usability for women to report toileting decisions, urination, and fluid intake. Future research using the app could test the influence of real-time factors on bladder health.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR1-10.2196/54046.
Stroke, trauma, and neurodegenerative disorders cause loss of neurites (axons and dendrites) in addition to neuronal death. Neurite loss may result directly from a primary insult, secondary to parental neuron death, or secondary to a post-injury inflammatory response. Here, we use lipopolysaccharide and the alarmin S100β to selectively evaluate neurite loss caused by the inflammatory response. Activation of microglia and infiltrating macrophages by these stimuli causes neurite loss that far exceeds neuronal death, both in vitro and in vivo. Neurite loss is accompanied by the formation of cofilactin rods and aggregates (CARs), which are polymers of cofilin-1 and actin induced by oxidative stress and other factors. Mice deficient in either cofilin-1 or the superoxide-generating enzyme NADPH oxidase-2 show reduced CAR formation, neurite loss, and motor impairment. The findings identify a mechanism by which inflammation leads to neurite loss via CAR formation and highlight the relevance of neurite loss to functional impairment.
PURPOSE:To strengthen the chemical bond propety with antigens or antibodies by a method whereine stylen or stylene and another monomer polymerizable therewith are polymerized in water with peroxosulfate as initiator without the presence of emulsifier and a compound containing amine reacts chemically upon a polymer particles in the suspension to have an amino group existing therein. CONSTITUTION:When a polymer particle is produced by polymerizing stylene with peroxosulfate as initiator, -SO3<-> on the surface of the polymer particle is changed to -OH group by hydrolysis. But when in the hydrolysis, the particle is subjected to a long-time heating in the coexistence of oxygen, it is oxidized to the extent of turning -OH group to -COOH group. Even in this case, with the polymer particle contacting alkylene imine such as ethyleneimine and propyleneimine, -COOH group on the surface of the particle is changed by chemical reaction with alkyleneimine to form a primary amine. Thus, amino group exists in the particle. In addition, when the stylene and another polymer polymerizable therewith are polymerized, -SO3<-> can be changed to -COOH group by hydrolysis thereof on the surface of the polymer particle through heating of the suspension.
PURPOSE: To provide a method for producing a carbon dioxide assimilation activating agent and a health food containing the same. CONSTITUTION: The method for producing a carbon dioxide assimilation activating agent comprises immersing frizzled edible plants or their crushed materials as a raw material into a seawater contained in a vessel by 30-50% amount of the seawater and closing a lid of the vessel, leaving the vessel under 5-50 deg.C atmosphere for approximately 4 days and collecting water droplets attached to the lid.  Also, a health food is obtained by frizzling and crushing unpolished rice, soybean and sesame, blending them so as to become 8-10 pts. unpolished rice, 8-10 pts. soybean and 0.1-0.3 pt. sesame for making a primary raw material, blending a mixed liquid obtained by blending the above carbon dioxide assimilation activating agent and a citron juice by 1:1 ratio with the primary raw material by 20-40% amount of the primary raw material to form a secondary raw material, agitating the secondary raw material in a fermenting room and filling carbon dioxide gas while adjusting a room temperature in the range of 5-50 deg.C and taking it out within 7 days from the fermenting room.
The discovery of "mismatch repair deficient (MMRd)-crypt foci" in non-neoplastic intestinal mucosa in Lynch syndrome (LS) has significantly enhanced our understanding of how tumors and tumor immunity form and evolve in LS. In this study, we report the frequent presence of "mismatch repair proficient (MMRp)-crypt foci" in both non-neoplastic and neoplastic intestinal mucosa in a patient with constitutional MMR deficiency (CMMRD), who carried a germline MSH6 pathogenic variant (c.3261dupC) in trans with an MSH6 likely pathogenic variant (c.3724_3726del) and whose tissues were otherwise deficient in MMR globally. The MMRp-crypts occurred at a rate of 1.1/100 crypts in non-neoplastic intestinal mucosa and were readily discernible in adenomas > 1 cm. Sequencing analysis revealed normalization of the MSH6c.3261dupC variant in MMRp-adenoma crypts, indicating reverse frameshifting of the exon 5 C8 microsatellite. Interestingly but not surprisingly, the MMRp-adenoma crypts remained microsatellite-instability-high (MSI-H), and shared oncogenic APC mutations with the background MMRd-adenoma. Contrasting with MSH6-CMMRD, no PMS2-CMMRD individuals (0/5) harbored MMRp-crypts. In conclusion, our study documents distinct MMRp-crypts in MSH6-CMMRD, a phenomenon in keeping with MSH6 being a frequent target of MSI-H due to its coding microsatellite and suggesting that MSH6-CMMRD can potentially serve as a unique model system to further our understanding of MSH6's role in MSI-H tumor formation and evolution. Our findings also bear diagnostic implications; when using MMR immunohistochemistry as an ancillary tool in detecting CMMRD, awareness of these MMRp crypts can help avoid diagnostic pitfalls.
Depression is common among persons with epilepsy (PwE), affecting roughly one in three individuals, and its presence is associated with personal suffering, impaired quality of life, and worse prognosis. Despite the availability of effective treatments, depression is often overlooked and treated inadequately in PwE, in part because of concerns over drug interactions. Previous studies strongly suggest that cognitive behavioral therapy (CBT) can help alleviate depression in PwE, but CBT is not always available to patients. Internet-administered psychological interventions are easily accessible and might complement antidepressant medication or psychotherapy, and preliminary evidence suggests that such interventions can be effective. However, no trial has yet examined whether a CBT-based internet intervention designed to meet the needs of PwE can achieve sustained reductions in depression and related symptoms, such as anxiety, when offered as adjunct to treatment as usual.

The Internet-based intervention evaluated in this trial was designed with the aim of conveying evidence-based psychotherapeutic techniques, gleaned primarily from CBT, to PwE over a period of 180 days. The intervention focuses on identifying and challenging cognitions that trigger or sustain depression and anxiety, increasing activities that are likely to reduce depression and anxiety, practicing relaxation and stress management exercises and increasing mindfulness skills. The program is based on general CBT and other evidence-based psychotherapeutic techniques that have been shown to be helpful for patients suffering from depression (and ideally, that have been shown to be helpful among PwE). Furthermore, program content addresses other issues in disease self-management, including lifestyle habits (e.g., nutrition, exercise) and medication adherence. The delivery and training of content is continuously individualized to match users' preferences and needs, based on responses within the program. The intervention is delivered via the Internet and protected by individually assigned passwords.

This randomized controlled trial will include 200 participants with epilepsy and a current depressive disorder, along with currently at least moderately elevated depression. Participants will be recruited from various settings, including epilepsy treatment clinics, outpatient treatment centers, and Internet forums/groups. Methods such as newspaper articles, flyers, posters, and media articles or web-advertisements will be used to inform potential participants about the study (all material will be in German). Participants will be randomly assigned to either (1) a control group, in which they receive care as usual (CAU) and are given access to the internet intervention (Desiconnect) after a delay of 3 months (i.e., CAU/Wait list control group), or (2) a treatment group that may also use CAU and in addition immediately receives six-month access to the novel, internet-administered intervention (Desiconnect). Measurements are collected online at pre-treatment (baseline, T0), three months (T1), six months (T2), and nine months (T3).